At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Aliskiren +1 moredrug
Likely dose
Aliskiren 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Renin Inhibition on Cardiovascular Autonomic Nerve Function in Diabetes
In Brief
A clinical study evaluating Aliskiren and Placebo for Diabetes. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This study will assess the effect of direct renin inhibition on nerve function in persons with diabetes using a double-blind, placebo-controlled randomized trial involving two treatment arms (i.e., \[1\] 30 participants enrolled and randomized to 300 mg of Aliskiren; \[2\] 30 participants enrolled and randomized to placebo).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionOct 2011
Study CompletionApr 2012
TodayJul 2026
First PostedJul 8, 2009
Enrollment StartJun 1, 2009
Primary CompletionOct 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.0 years ago
Interventions
Aliskirendrug
Pill, 300 mg, once daily, for 6 weeks
Placeboother
Placebo orally one tablet once a day for 6 weeks.